Vinorelbine Lotus 30 mg soft capsule Malta - English - Medicines Authority

vinorelbine lotus 30 mg soft capsule

lotus support services s.r.l. 47 theodor pallady blvd. 2nd office, entrance b, 1st floor 3rd district bucharest, romania - vinorelbine tartrate - soft capsule - vinorelbine tartrate 30 mg - antineoplastic agents

Vinorelbine Lotus 80 mg soft capsule Malta - English - Medicines Authority

vinorelbine lotus 80 mg soft capsule

lotus support services s.r.l. 47 theodor pallady blvd. 2nd office, entrance b, 1st floor 3rd district bucharest, romania - vinorelbine tartrate - soft capsule - vinorelbine tartrate 80 mg - antineoplastic agents

VINORELBINE injection, solution United States - English - NLM (National Library of Medicine)

vinorelbine injection, solution

sagent pharmaceuticals - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml - vinorelbine injection is indicated: - in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) - as a single agent for the treatment of patients with metastatic nsclc none risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1)] , vinorelbine can cause fetal harm when administered to a pregnant woman. available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively (see data) . advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and

Teva-Vinorelbine 10 mg Infusion Namibia - English - Namibia Medicines Regulatory Council

teva-vinorelbine 10 mg infusion

teva pharmaceuticals (pty) ltd - vinorelbine tartrate - injection - each 1 ml vial contains; vinorelbine tartrate equivalent to vinorelbine 10,0 mg

VINORELBINE injection, solution United States - English - NLM (National Library of Medicine)

vinorelbine injection, solution

actavis pharma, inc. - vinorelbine tartrate (unii: 253gqw851q) (vinorelbine - unii:q6c979r91y) - vinorelbine 10 mg in 1 ml - vinorelbine injection is indicated: - in combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) - as a single agent for the treatment of patients with metastatic nsclc none risk summary based on findings from animal studies and its mechanism of action [see clinical pharmacology (12.1)], vinorelbine can cause fetal harm when administered to a pregnant woman. available human data are insufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies in mice and rabbits, embryo and fetal toxicity were observed with administration of vinorelbine at doses approximately 0.33 and 0.18 times the human therapeutic dose, respectively (see data). advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 1

VINORELBINE TARTRATE FOR INJECTION SOLUTION Canada - English - Health Canada

vinorelbine tartrate for injection solution

teva canada limited - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents

Vinorelbine Ebewe New Zealand - English - Medsafe (Medicines Safety Authority)

vinorelbine ebewe

sandoz new zealand limited - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine excipient: water for injection - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first-line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Vinorelbine Accord 20 mg soft capsules Ireland - English - HPRA (Health Products Regulatory Authority)

vinorelbine accord 20 mg soft capsules

accord healthcare ireland ltd. - vinorelbine tartrate - capsule, soft - vinorelbine

Vinorelbine Accord 30 mg soft capsules Ireland - English - HPRA (Health Products Regulatory Authority)

vinorelbine accord 30 mg soft capsules

accord healthcare ireland ltd. - vinorelbine tartrate - capsule, soft - vinorelbine

VINORELBINE TARTRATE INJECTION USP SOLUTION Canada - English - Health Canada

vinorelbine tartrate injection usp solution

sandoz canada incorporated - vinorelbine (vinorelbine tartrate) - solution - 10mg - vinorelbine (vinorelbine tartrate) 10mg - antineoplastic agents